Major adverse reactions to antituberculosis drugs can cause significant morbidity, and
compromise treatment regimens for tuberculosis (TB). Among patients treated for active TB we …

Background A 9-month regimen of isoniazid can prevent active tuberculosis in persons with
latent tuberculosis infection. However, the regimen has been associated with poor …

Background The treatment of latent infection with Mycobacterium tuberculosis is important in
children because of their vulnerability to life-threatening forms of tuberculosis disease. The …

Background An important problem limiting treatment of latent tuberculosis infection is the
occurrence of adverse events with isoniazid. We combined populations from phase 2 and …

Background Reaching the UN General Assembly High-Level Meeting on Tuberculosis
target of providing tuberculosis preventive treatment to at least 30 million people by 2022, …

Background Tuberculosis preventive treatment (TPT) is a key component of tuberculosis
elimination. To improve completion and reduce the burden for people and health systems, short…

Introduction Treatment of latent tuberculosis (TB) infection (LTBI) is an important component
of the End-TB strategy. However, the number of individuals who successfully complete LTBI …

Background Loss of patients in the latent tuberculosis infection (LTBI) cascade of care is a
major barrier to LTBI management. We evaluated the impact and acceptability of local …

Background In a cluster randomized trial (clinicaltrials.gov: NCT02810678) a flexible but
comprehensive health system intervention significantly increased the number of household …

Background The Tuberculin Skin Test (TST) is a relatively simple test for detecting latent
tuberculosis infection (LTBI) but requires regular quality assurance to ensure proper technique …